News

ISPOR held a plenary session today, “Health Economics and Outcomes Research (HEOR) in the Era of COVID-19,” that featured a number of HEOR and health policy thought leaders discussing the rapidly evolving global COVID-19 crisis and the implications for short-term and long-term healthcare decisions.

ISPOR confirmed the program today for Virtual ISPOR 2020, "HEOR: Advancing Evidence to Action.” The virtual conference is offering nearly 60 hours of content that registrants can attend live and/or on demand through June 30, 2020.

ISPOR announced that it has posted a COVID-19 News webpage to provide members and other healthcare stakeholders with information and resources related to the COVID-19 virus, curating content that intersects with health economics and outcomes research (HEOR).

ISPOR announced the program and speakers for Virtual ISPOR 2020. The Society redesigned its annual, international conference as a virtual event due to the COVID-19 pandemic.

Value in Health announced the publication of a series of articles providing perspectives on biopharmaceutical value-based contracting and what the future may hold for risk-sharing arrangements.

Value in Health announced the publication of new research showing that uptake of lung cancer screening may depend on making testing fast and convenient.

Value in Health announced the publication of an article highlighting US Food and Drug Administration (FDA) guidance and lessons learned regarding the use of patient preference information for FDA decision making about medical devices

ISPOR announced that its annual, international conference has been reimagined due to the COVID-19 pandemic and will now take place as a virtual conference.

Value in Health, the official journal of ISPOR, announced today the publication of 2 Good Practices Reports that together describe the findings of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.

Value in Health, the official journal of ISPOR, announced today the publication of new research showing that insurer approval rates for PCSK9i prescriptions remain low.